Developing mRNA medicines to restore protein function.

We are a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

Learn More

Translate Bio

We are pioneering the translation of mRNA therapeutics into transformative medicines.

Recent News

01.22 2019
Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
01.03 2019
Translate Bio Advances Programs in Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
01.03 2019
Translate Bio Appoints Robert Meyer, MD, to its Board of Directors
12.04 2018
Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT™)

View All

@TranslateBio